Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and PK Study of AK0529 in Healthy Human

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02297594
Recruitment Status : Completed
First Posted : November 21, 2014
Last Update Posted : October 20, 2015
Sponsor:
Information provided by (Responsible Party):
Ark Biosciences Inc.

Brief Summary:
The purpose of this study is to assess the safety, tolerability and PK of single and multiple ascending dose of AK0529 when administered orally in healthy subjects

Condition or disease Intervention/treatment Phase
Respiratory Syncytial Virus Infections Drug: AK0529 Drug: Placebo Phase 1

Detailed Description:
This is a Phase 1, first-in-man, single-center, randomized, double blind, placebo controlled single and multiple ascending dose study in healthy male and female volunteers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of AK0529 When Administered Orally in Healthy Male and Female Adult Subjects
Study Start Date : October 2014
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: AK0529
Generic name: AK0529 Dosage Form: capsule
Drug: AK0529
AK0529 capsule for oral administration
Other Name: AK0529 capsule

Placebo Comparator: Placebo
Sugar placebo
Drug: Placebo
Sugar placebo capsule for oral administration
Other Name: Sugar placebo capsule




Primary Outcome Measures :
  1. Number of participants with adverse events, serious adverse events [ Time Frame: Screening to Day 14 - 21 ]

Secondary Outcome Measures :
  1. Pharmacokinetics of single dose study: Area Under Curve (AUC) [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose ]
  2. Pharmacokinetics of single dose study: Observed Maximum plasma concentration (Cmax) [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose ]
  3. Pharmacokinetics of single dose study: half-life (t1/2) [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose ]
  4. Pharmacokinetics of single dose study: time to maximum plasma concentration (tmax) [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose ]
  5. Pharmacokinetics of single dose study: Volume of distribution [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose ]
  6. Pharmacokinetics of single dose study: Clearance [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose ]
  7. Pharmacokinetics of multiple dose study:Area Under Curve (AUC) [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9) ]
  8. Pharmacokinetics of multiple dose study: Observed Maximum plasma concentration (Cmax) [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9) ]
  9. Pharmacokinetics of multiple dose study: half-life (t1/2) [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9) ]
  10. Pharmacokinetics of multiple dose study: time to maximum plasma concentration (tmax) [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9) ]
  11. Pharmacokinetics of multiple dose study:Volume of distribution [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9) ]
  12. Pharmacokinetics of multiple dose study: clearance [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Must be healthy males, or healthy females of non-childbearing potential or surgically sterilized or post-menopausal (amenorrhea for at least 1 year and confirmed by a follicle stimulating hormone [FSH] result of > 20 IU/mL).
  2. Must be aged 18 to 55 years of age inclusive.
  3. Must have body mass index (BMI) of 18.0 to 31.0 kg/m2 inclusive.
  4. Must have total body weight ≥50 kg at screening but ≤100 Kg.
  5. Must be willing and able to communicate and participate in the whole study.
  6. Must provide written informed consent.
  7. Must agree to use an adequate method of contraception (as defined in Section 4.2.1).
  8. Must have AST, ALT, total bilirubin, urea, creatinine and hemoglobin within the laboratory reference range at screening and Day -1.
  9. Must have QTcF <450 ms, QTcB <450 ms and PR interval <210 ms for screening, Day -1 and pre-dose ECG measurements, and not have any degree of heart block or conduction abnormality.
  10. Must have serology demonstrating they are free from infection with hepatitis B, hepatitis C, and human immunodeficiency virus (HIV-1 and HIV-2)

Exclusion Criteria:

  1. Male subjects who have currently pregnant partners or who have partners planning to become pregnant during the duration of the study.
  2. Evidence or history of clinical significant oncological, pulmonary, chronic respiratory, hepatic, cardiovascular, hematological, metabolic, neurological, immunological, nephrological, endocrine or psychiatric disease, or current infection.
  3. Clinically relevant (as decided by the investigator and the medical monitor) abnormalities in the ECG (12 standard leads) including any degree of heart block, including asymptomatic bundle branch block.
  4. Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.
  5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.
  6. Electrolyte disturbances, particularly hypokalemia hypocalcemia or hypomagnesemia.
  7. Any condition that could possibly affect drug absorption, e.g. gastrectomy or diarrhea.
  8. History of post-antibiotic colitis.
  9. History of any drug or alcohol abuse in the past 2 years prior to screening.
  10. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = 400 mL beer, 25 mL of 40% spirit or a 75 mL glass of wine).
  11. Subjects who have a urine cotinine greater than 500 ng/mL at screening will be excluded. Subjects who are tobacco users (including smokers and users of snuff, chewing tobacco and other nicotine or nicotine-containing products) must have stopped use at least 90 days before screening.
  12. Receipt of an investigational drug or participation in another clinical research study within 90 days prior to drug administration.
  13. Subjects who are study site employees, or immediate family members of a study site or sponsor employee.
  14. Subjects who have previously been enrolled and dosed in this study, except subjects undergoing repeat dosing in Cohort 4F (the fed PK cohort of the SAD part of the study).

Other protocol defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02297594


Locations
Layout table for location information
Australia, Queensland
Q-Pharm Pty Ltd QIMR Berghofer & Royal Brisbane and Women's Hospital Campus
Brisbane, Queensland, Australia, 4006
Sponsors and Collaborators
Ark Biosciences Inc.
Investigators
Layout table for investigator information
Principal Investigator: Paul Griffin, MD Q-Pharm Pty Ltd
Layout table for additonal information
Responsible Party: Ark Biosciences Inc.
ClinicalTrials.gov Identifier: NCT02297594    
Other Study ID Numbers: AK0529-1001
First Posted: November 21, 2014    Key Record Dates
Last Update Posted: October 20, 2015
Last Verified: October 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Syncytial Virus Infections
Virus Diseases
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections